SPECTRA PGx

Personalized Diagnostic Solutions. Recovery Focused. Outcomes Driven.

Spectra PGx provides an evidence based objective tool to better predict medication response giving clinically actionable personalized diagnostic solutions shown to reduce healthcare spend and improve patient outcomes.

TO VIEW OUR PHARMACOGENETICS MENU

Why Use/Order PGx Testing?

  • Reduce medication trial and error
  • PGx provides a more effective path to optimize medication management via a quick non invasive diagnostic tool
  • Reduce hospital readmission rates
  • Reduce ADR’s
  • Improve outcomes
    • Right medication, right dose earlier in treatment
  • Increase patient compliance

80% of patients who have failed at least one medication are currently taking a genetically sub-optimal medication.1

Scenario: A set of depressed patients awaiting prescription of the SSRI paroxetine (Paxil)

PGx Scenario
16 Genes tested across 10 Therapeutic areas:

Psychiatry
Pain

ADHD
Anticonvulsant

Antidepressant
Opioid

Benzodiazepine
Muscle Relaxant

NSAID
Antipsychotic

Companion Diagnostics

MAT + PGx = PERSONALIZED HEALTHCARE SOLUTIONS

94% of the general population have at least 1 variant for the CYP450 Genes responsible for metabolizing 60% of commonly prescribed medications.3

CYP450 FAMILY: CYP2D6 VARIANT PATIENTS HAVE HIGHER COST TO CARE 4
30 60 percent increase
7 days longer
2x more

When to Consider PGx Testing

  • Upon intake: Getting to the right drug and dosage early in treatment
  • Unexpected or past therapy failures
  • Adverse drug events
  • Patients requiring higher than recommended doses
  • Patients with multiple medications prescribed
  • Patients demonstrating sensitivity or reduced symptom relief

30-40% of opioid and antipsychotic medications are ineffective for treatment in the patient population.2

  1. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discovery Med. 2013;16(89): 219-227 2.
  2. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-204. Ross JS, Ginsburg GS. The Integration of molecular diagnostics with therapeutics;Implications for drug development and pathology practice. Am J Clin Pathol.2003;119:26-36. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid- naive patients with chronic low back pain. Curr Med Res Opin. 2007;23:117–128. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain. 2010;26(1):S16-20.
  3. Verbeurgt, P, Mamiya, T, Oesterheld, J, et al.. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655–665.
  4. Chou WH, et al. Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental Illness. J Clin Pyschopharmacol. 2000;20(2):246-251.
Menu